ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
ProMIS Neurosciences appointed Ivana Rubino, Ph.D., as Chief Commercial Officer, effective October 5, 2026. Rubino spent more than 15 years at Biogen and Roche, most recently as VP and Global Head of Alzheimer's Disease & Multiple Sclerosis Medical at Biogen, supporting the LEQEMBI franchise across 52 market approvals. She will lead commercial and launch-readiness strategy for PMN310 ahead of unblinded 12-month PRECISE-AD topline data expected in Q1 2027.
Key figures
- Option term years
- 10
- Inducement option shares
- 80000
- Inducement option exercise price
- 9.37
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.